These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 22251274)

  • 21. NT-proBNP in chronic hypercapnic respiratory failure: a marker of disease severity, treatment effect and prognosis.
    Budweiser S; Luchner A; Jörres RA; Heinemann F; Hitzl AP; Schmidbauer K; Riegger G; Pfeifer M
    Respir Med; 2007 Sep; 101(9):2003-10. PubMed ID: 17532200
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Usefulness of clinical and NT-proBNP monitoring for prognostic guidance in destabilized heart failure outpatients.
    Pascual-Figal DA; Domingo M; Casas T; Gich I; Ordoñez-Llanos J; Martínez P; Cinca J; Valdés M; Januzzi JL; Bayes-Genis A
    Eur Heart J; 2008 Apr; 29(8):1011-8. PubMed ID: 18263871
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brain natriuretic peptide and N-terminal proBNP in chronic haemodialysis patients.
    Racek J; Králová H; Trefil L; Rajdl D; Eiselt J
    Nephron Clin Pract; 2006; 103(4):c162-72. PubMed ID: 16645318
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure.
    de Antonio M; Lupon J; Galan A; Vila J; Urrutia A; Bayes-Genis A
    Am Heart J; 2012 May; 163(5):821-8. PubMed ID: 22607860
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study.
    Bhardwaj A; Rehman SU; Mohammed A; Baggish AL; Moore SA; Januzzi JL
    Am Heart J; 2010 Apr; 159(4):532-538.e1. PubMed ID: 20362709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. N-terminal pro B-type natriuretic peptide in the early evaluation of suspected acute myocardial infarction.
    Haaf P; Balmelli C; Reichlin T; Twerenbold R; Reiter M; Meissner J; Schaub N; Stelzig C; Freese M; Paniz P; Meune C; Drexler B; Freidank H; Winkler K; Hochholzer W; Mueller C
    Am J Med; 2011 Aug; 124(8):731-9. PubMed ID: 21787902
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased plasma concentrations of N-terminal pro-B-type natriuretic peptide in patients with mild primary hyperparathyroidism.
    Almqvist EG; Becker C; Bondeson AG; Bondeson L; Svensson J; Svensson SE
    Clin Endocrinol (Oxf); 2006 Dec; 65(6):760-6. PubMed ID: 17121527
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population.
    Lam CS; Burnett JC; Costello-Boerrigter L; Rodeheffer RJ; Redfield MM
    J Am Coll Cardiol; 2007 Mar; 49(11):1193-202. PubMed ID: 17367664
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial.
    Omland T; Sabatine MS; Jablonski KA; Rice MM; Hsia J; Wergeland R; Landaas S; Rouleau JL; Domanski MJ; Hall C; Pfeffer MA; Braunwald E;
    J Am Coll Cardiol; 2007 Jul; 50(3):205-14. PubMed ID: 17631211
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic accuracy of plasma brain natriuretic peptide and aminoterminal-proBNP in mild heart failure depends on assay and introduction of therapy.
    Mikkelsen KV; Bie P; Møller JE; Ryde H; Videbaek L; Haghfelt T
    Scand J Clin Lab Invest; 2005; 65(8):633-47. PubMed ID: 16319038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amino-terminal pro-B-type natriuretic peptide testing for the diagnosis or exclusion of heart failure in patients with acute symptoms.
    Januzzi JL; Chen-Tournoux AA; Moe G
    Am J Cardiol; 2008 Feb; 101(3A):29-38. PubMed ID: 18243855
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Importance of early combined N-terminal pro-brain natriuretic peptide and cardiac troponin T measurements for long-term risk stratification of patients with decompensated heart failure.
    Perna ER; Macin SM; Cimbaro Canella JP; Szyszko A; Franciosi V; Vargas Morales W; Bayol AP; Kriskovich JO; Medina F; Gonzalez Arjol B; Brizuela M
    J Heart Lung Transplant; 2006 Oct; 25(10):1230-40. PubMed ID: 17045936
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amino-terminal pro-B-type natriuretic peptide testing for inpatient monitoring and treatment guidance of acute destabilized heart failure.
    Bettencourt P; Januzzi JL
    Am J Cardiol; 2008 Feb; 101(3A):67-71. PubMed ID: 18243862
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial).
    Masson S; Latini R; Anand IS; Barlera S; Angelici L; Vago T; Tognoni G; Cohn JN;
    J Am Coll Cardiol; 2008 Sep; 52(12):997-1003. PubMed ID: 18786480
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Head to head comparison of N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in patients with/without left ventricular systolic dysfunction.
    Vanderheyden M; Bartunek ; Claeys G; Manoharan G; Beckers JF; Ide L
    Clin Biochem; 2006 Jun; 39(6):640-5. PubMed ID: 16516185
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic accuracy of B type natriuretic peptide and amino terminal proBNP in the emergency diagnosis of heart failure.
    Mueller T; Gegenhuber A; Poelz W; Haltmayer M
    Heart; 2005 May; 91(5):606-12. PubMed ID: 15831643
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma N-terminal pro-brain natriuretic peptide and brain natriuretic peptide in assessment of acute dyspnea.
    Alibay Y; Beauchet A; El Mahmoud R; Schmitt C; Brun-Ney D; Benoit MO; Dubourg O; Boileau C; Jondeau G; Puy H
    Biomed Pharmacother; 2005; 59(1-2):20-4. PubMed ID: 15740931
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of plasma N-terminal pro-B-type natriuretic peptide with postoperative cardiac events in patients undergoing surgery for abdominal aortic aneurysm or leg bypass.
    Feringa HH; Bax JJ; Elhendy A; de Jonge R; Lindemans J; Schouten O; van den Meiracker AH; Boersma E; Schinkel AF; Kertai MD; van Sambeek MR; Poldermans D
    Am J Cardiol; 2006 Jul; 98(1):111-5. PubMed ID: 16784932
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study.
    Anwaruddin S; Lloyd-Jones DM; Baggish A; Chen A; Krauser D; Tung R; Chae C; Januzzi JL
    J Am Coll Cardiol; 2006 Jan; 47(1):91-7. PubMed ID: 16386670
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The biologic variability of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in stable heart failure patients.
    O'Hanlon R; O'Shea P; Ledwidge M; O'Loughlin C; Lange S; Conlon C; Phelan D; Cunningham S; McDonald K
    J Card Fail; 2007 Feb; 13(1):50-5. PubMed ID: 17339003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.